Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2021-11-16 00:00:00 ET · period of report 2021-11-16 · accession 0001209191-21-064924 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-16 | 2021-11-16 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $2.23 | +30.0K | 90.0K | +50% | +$66.9K |
| D | 2021-11-16 | 2021-11-16 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $0.00 | -30.0K | 103.3K | -23% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-16 | M | A | 30,000 | $2.23 | 90,000 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2021-11-16 | M | D | 30,000 | $0.00 | 103,294 | D | $2.23 · — to 2028-11-27 | 30,000 Common Stock | (F1) The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. |